This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lee, J. I. Articles by Mao, L. Search for Related Content PubMed PubMed Citation Articles by Lee, J. I. Articles by Mao, L.

Loss of Fhit Expression Is a Predictor of Poor Outcome in Tongue Cancer¹

Departments of Thoracic/Head and Neck Medical Oncology [J. I. L., J-C. S., K. H., D. L., X. T., W. K. H., L. M.] and Pathology, Molecular Biology Laboratory, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030 [A. E-N.]

Abnormalities of FHIT, a candidate tumor suppressor gene located at 3p14.2, have been found frequently in multiple tumor types, including head and neck squamous cell carcinoma. To determine the role of FHIT in tongue cancers, Fhit expression was determined by immunohistochemistry studies in tissue samples from 41 patients with stages II–IV squamous cell carcinomas of the tongue. All of the patients underwent curative surgical treatment with a median of 83 months of follow-up care. We found that 28 (68%) of the 41 tumor specimens demonstrated a lack of or significantly decreased staining for Fhit. Fhit expression tended to be stronger in well-differentiated tumor areas than it was in poorly differentiated areas, although this trend was not statistically significant. There was no significant correlation between Fhit expression and a patient’s age or sex or the histological grade or clinical stage of disease. As expected, clinical stage and nodal involvement correlated with prognosis. Interestingly, patients whose tumors demonstrated low levels of or no Fhit expression had a significantly shorter time of disease-free survival than those whose tumors had high Fhit expression (P = 0.035, by log-rank test). This prognostic value of Fhit was independent of other clinical parameters, including stage of disease and nodal status. We conclude that Fhit plays an important role in the development of squamous cell carcinomas of the tongue and that loss of Fhit expression may be an independent prognostic indicator for clinical outcome in patients with this tumor type.

This article has been cited by other articles:

				I. F.L. Tsui, M. P. Rosin, L. Zhang, R. T. Ng, and W. L. Lam Multiple Aberrations of Chromosome 3p Detected in Oral Premalignant Lesions Cancer Prevention Research, November 1, 2008; 1(6): 424 - 429. [Abstract] [Full Text] [PDF]

				O. Kujan, R. Oliver, L. Roz, G. Sozzi, N. Ribeiro, R. Woodwards, N. Thakker, and P. Sloan Fragile Histidine Triad Expression in Oral Squamous Cell Carcinoma and Precursor Lesions. Clin. Cancer Res., November 15, 2006; 12(22): 6723 - 6729. [Abstract] [Full Text] [PDF]

				S.-K. Tai, J. I. Lee, K. K. Ang, A. K. El-Naggar, K. A. Hassan, D. Liu, J. J. Lee, H. Ren, W. K. Hong, and L. Mao Loss of Fhit Expression in Head and Neck Squamous Cell Carcinoma and Its Potential Clinical Implication Clin. Cancer Res., August 15, 2004; 10(16): 5554 - 5557. [Abstract] [Full Text] [PDF]

				C. Garnis, C. Baldwin, L. Zhang, M. P. Rosin, and W. L. Lam Use of Complete Coverage Array Comparative Genomic Hybridization to Define Copy Number Alterations on Chromosome 3p in Oral Squamous Cell Carcinomas Cancer Res., December 15, 2003; 63(24): 8582 - 8585. [Abstract] [Full Text] [PDF]

				A. G. Banerjee, V. K. Gopalakrishnan, I. Bhattacharya, and J. K. Vishwanatha Deregulated Cyclooxygenase-2 Expression in Oral Premalignant Tissues Mol. Cancer Ther., December 1, 2002; 1(14): 1265 - 1271. [Abstract] [Full Text] [PDF]

				Q. Yang, M. Nakamura, Y. Nakamura, G. Yoshimura, T. Suzuma, T. Umemura, Y. Shimizu, I. Mori, T. Sakurai, and K. Kakudo Two-Hit Inactivation of FHIT by Loss of Heterozygosity and Hypermethylation in Breast Cancer Clin. Cancer Res., September 1, 2002; 8(9): 2890 - 2893. [Abstract] [Full Text] [PDF]

				Q. Yang, G. Yoshimura, T. Suzuma, T. Tamaki, T. Umemura, M. Nakamura, Y. Nakamura, X. Wang, I. Mori, T. Sakurai, et al. Clinicopathological Significance of Fragile Histidine Triad Transcription Protein Expression in Breast Carcinoma Clin. Cancer Res., December 1, 2001; 7(12): 3869 - 3873. [Abstract] [Full Text] [PDF]

				H. Ishii, K. R. Dumon, A. Vecchione, L. Y. Y. Fong, R. Baffa, K. Huebner, and C. M. Croce Potential Cancer Therapy With the Fragile Histidine Triad Gene: Review of the Preclinical Studies JAMA, November 21, 2001; 286(19): 2441 - 2449. [Abstract] [Full Text] [PDF]

				N. Zanesi, V. Fidanza, L. Y. Fong, R. Mancini, T. Druck, M. Valtieri, T. Rudiger, P. A. McCue, C. M. Croce, and K. Huebner The tumor spectrum in FHIT-deficient mice PNAS, August 17, 2001; (2001) 191345898. [Abstract] [Full Text] [PDF]

				N. Zanesi, V. Fidanza, L. Y. Fong, R. Mancini, T. Druck, M. Valtieri, T. Rudiger, P. A. McCue, C. M. Croce, and K. Huebner The tumor spectrum in FHIT-deficient mice PNAS, August 28, 2001; 98(18): 10250 - 10255. [Abstract] [Full Text] [PDF]